Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916151 | 0.81 | KDM4E (0.31) | KDM4EMAPT | |
| SCHEMBL20226560 | 0.79 | MCHR1 (0.35) | — | |
| SCHEMBL1496790 | 0.77 | ALDH1A1 (0.31) | ALOX5APFEN1 | |
| SCHEMBL20149143 | 0.77 | HSD17B10 (0.38) | ALOX5APFEN1KDM4EMAPTCRHBP | |
| SCHEMBL11916153 | 0.72 | RAPGEF4 (0.30) | — | |
| SCHEMBL11916149 | 0.72 | SLC6A2 (0.38) | KDM4EMAPT | |
| SCHEMBL20223444 | 0.72 | ALOX5AP (0.32) | ALOX5APFEN1 | |
| SCHEMBL10259660 | 0.70 | CA1 (0.31) | — | |
| SCHEMBL8570914 | 0.70 | SLC6A2 (0.41) | ALOX5APFEN1 | |
| SCHEMBL14453810 | 0.69 | TLR8 (0.36) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2018089373-A9 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018089373-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | ALOX5AP 3138/4885FEN1 3247/4885KDM4E 4467/4885 |
| US-10711032-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | ALOX5AP 3138/4885FEN1 3247/4885KDM4E 4467/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | ALOX5AP 3093/4885FEN1 3323/4885KDM4E 4484/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | ALOX5AP 3093/4885FEN1 3323/4885KDM4E 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.